Pre-treatment with systemic agents for advanced NSCLC elicits changes in the phenotype of autologous T cell therapy products

June, 2018, CAR T cell immunotherapy for human cancer, Science, 359, 1361, 10.1126/science.aar6711 Irvine, 2022, The future of engineered immune cell therapies, Science, 378, 853, 10.1126/science.abq6990 Centers for Disease Control and Prevention Harrison, 2008, Airway infiltration of CD4+ CCR6+ Th17 type cells associated with chronic cigarette smoke induced airspace enlargement, Immunol. Lett., 121, 13, 10.1016/j.imlet.2008.07.011 Vargas-Rojas, 2011, Increase of Th17 cells in peripheral blood of patients with chronic obstructive pulmonary disease, Respir. Med., 105, 1648, 10.1016/j.rmed.2011.05.017 Nakata, 2007, Relationship between cumulative effects of smoking and memory CD4+ T lymphocyte subpopulations, Addict Behav., 32, 1526, 10.1016/j.addbeh.2006.11.007 Vardavas, 2010, Passive smoking alters circulating naive/memory lymphocyte T-cell subpopulations in children, Pediatr. Allergy Immunol., 21, 1171, 10.1111/j.1399-3038.2010.01039.x McAllister-Sistilli, 1998, The effects of nicotine on the immune system, Psychoneuroendocrinology, 23, 175, 10.1016/S0306-4530(97)00080-2 Zimmermann, 2019, Factors That Influence the Immune Response to Vaccination, Clin. Microbiol. Rev., 32, 10.1128/CMR.00084-18 Arcavi, 2004, Cigarette smoking and infection, Arch. Intern. Med., 164, 2206, 10.1001/archinte.164.20.2206 2019 Pardoll, 2012, The blockade of immune checkpoints in cancer immunotherapy, Nat. Rev. Cancer, 12, 252, 10.1038/nrc3239 Kamphorst, 2017, Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients, Proc. Natl. Acad. Sci. USA, 114, 4993, 10.1073/pnas.1705327114 Adjei, 2004, Pharmacology and mechanism of action of pemetrexed, Clin. Lung Cancer, 5, S51, 10.3816/CLC.2004.s.003 Schaer, 2018, P1.04-07 Pemetrexed Enhances Anti-Tumor Efficacy of PD-L1 blockade by Promoting Intra-Tumor Immune Response via Tumor and T Cell-Intrinsic Mechanisms, J. Thorac. Oncol., 13, 10.1016/j.jtho.2018.08.722 Lu, 2020, Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy, J. Immunother. Cancer, 8 Curt, 1983, A phase I and pharmacokinetic study of diamminecyclobutane-dicarboxylatoplatinum (NSC 241240), Cancer Res., 43, 4470 Hong, 2023, Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer, Nat. Commun., 14, 695, 10.1038/s41467-023-36328-z Zhou, 2011, Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study, Lancet Oncol., 12, 735, 10.1016/S1470-2045(11)70184-X Wang, 2016, Amphiregulin Confers Regulatory T Cell Suppressive Function and Tumor Invasion via the EGFR/GSK-3beta/Foxp3 Axis, J. Biol. Chem., 291, 21085, 10.1074/jbc.M116.717892 Jia, 2019, EGFR-targeted therapy alters the tumor microenvironment in EGFR-driven lung tumors: Implications for combination therapies, Int. J. Cancer, 145, 1432, 10.1002/ijc.32191 Dominguez, 2016, Short-term EGFR blockade enhances immune-mediated cytotoxicity of EGFR mutant lung cancer cells: rationale for combination therapies, Cell Death Dis, 7, e2380, 10.1038/cddis.2016.297 He, 2013, Enhanced interaction between natural killer cells and lung cancer cells: involvement in gefitinib-mediated immunoregulation, J. Transl Med., 11, 186, 10.1186/1479-5876-11-186 Khan, 2018, ALK Inhibitors in the Treatment of ALK Positive NSCLC, Front Oncol., 8, 557, 10.3389/fonc.2018.00557 Iwahara, 1997, Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system, Oncogene, 14, 439, 10.1038/sj.onc.1200849 Oh, 2019, ALK and RET Inhibitors Promote HLA Class I Antigen Presentation and Unmask New Antigens within the Tumor Immunopeptidome, Cancer Immunol. Res., 7, 1984, 10.1158/2326-6066.CIR-19-0056 Fraietta, 2018, Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells, Nature, 558, 307, 10.1038/s41586-018-0178-z Miller, 2019, Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade, Nat. Immunol., 20, 326, 10.1038/s41590-019-0312-6 Benjamini, 1995, Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing, J. R. Stat. Soc. Ser. B (Methodological), 57, 289 Galletti, 2020, Two subsets of stem-like CD8(+) memory T cell progenitors with distinct fate commitments in humans, Nat. Immunol., 21, 1552, 10.1038/s41590-020-0791-5 Button, 2013, Power failure: why small sample size undermines the reliability of neuroscience, Nat. Rev. Neurosci., 14, 365, 10.1038/nrn3475 2011 Gyurdieva, 2022, Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma, Nat. Commun., 13, 5296, 10.1038/s41467-022-32491-x Roberto, 2015, Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation, Blood, 125, 2855, 10.1182/blood-2014-11-608406 Zhang, 2016, The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis, Oncotarget, 7, 78985, 10.18632/oncotarget.12587 Strioga, 2011, CD8+ CD28- and CD8+ CD57+ T cells and their role in health and disease, Immunology, 134, 17, 10.1111/j.1365-2567.2011.03470.x Kared, 2016, CD57 in human natural killer cells and T-lymphocytes, Cancer Immunol. Immunother., 65, 441, 10.1007/s00262-016-1803-z Mayer, 2011, CD8+ Foxp3+ T cells share developmental and phenotypic features with classical CD4+ Foxp3+ regulatory T cells but lack potent suppressive activity, Eur. J. Immunol., 41, 716, 10.1002/eji.201040913 Li, 2022, CD38: An important regulator of T cell function, Biomed. Pharmacother., 153, 113395, 10.1016/j.biopha.2022.113395 Nicolet, 2020, CD29 identifies IFN-gamma-producing human CD8(+) T cells with an increased cytotoxic potential, Proc. Natl. Acad. Sci. USA, 117, 6686, 10.1073/pnas.1913940117 Ferrara, 2021, Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy, Clin. Cancer Res., 27, 492, 10.1158/1078-0432.CCR-20-1420 Fehlings, 2019, Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment, J. Immunother. Cancer, 7, 249, 10.1186/s40425-019-0695-9 Kunert, 2019, CD45RA(+)CCR7(-) CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumab, J. Immunother. Cancer, 7, 149, 10.1186/s40425-019-0608-y Pangrazzi, 2020, CD28 and CD57 define four populations with distinct phenotypic properties within human CD8(+) T cells, Eur. J. Immunol., 50, 363, 10.1002/eji.201948362 Ayers, 2017, IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade, J. Clin. Invest, 127, 2930, 10.1172/JCI91190 Bourgeois-Daigneault, 2016, Oncolytic vesicular stomatitis virus expressing interferon-gamma has enhanced therapeutic activity, Mol. Ther. Oncolytics, 3, 16001, 10.1038/mto.2016.1 Choy Gu, 2023 Finck, 2013, Normalization of mass cytometry data with bead standards, Cytometry A, 83, 483, 10.1002/cyto.a.22271 Levine, 2015, Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis, Cell, 162, 184, 10.1016/j.cell.2015.05.047